HyperapoB is the commonest dyslipoproteinaemia associated with coronary disease [1, 2] and is characterized by an increased LDL particle number due to increased secretion of B100 lipoproteins by the liver [3] . The first feature of hyperapoB to be recognized was the elevated LDL particle number, many of which are smaller and denser than normal [4] . In reality, though, the metabolism of all the lipoprotein classes is demonstrably abnormal.
The normal sequence involved in the uptake by adipocytes of fatty acids released from chylomicrons can be summarized as follows: chylomicrons attach to endothelial cells and the triglyceride within them is rapidly hydrolysed by lipoprotein lipase (LPL) [5] . The rate at which chylomicron triglyceride hydrolysis proceeds is determined by the number of LPL molecules involved and by the rate at which the NEFA which are generated are removed from the capillary microenvironment.
The NEFA which are liberated from the chylomicrons can enter the adipocyte to be trapped within it as triglyceride. Alternatively, they may bind to albumin, leave the capillary, and enter the general circulation. The proportion of NEFA released from chylomicrons which enter adipocytes is necessarily the reciprocal of the proportion which are not trapped by adipocytes and which then leave the microenvironment. Under normal circumstance, the proportions are about equal [6] . The proportion of NEFA which are trapped by adipocytes is determined by their rate of triglyceride synthesis, the major determinant of which is the acylation stimulating protein (ASP) pathway [7] .
ASP is the product of the ASP pathway and, as just noted, is the major determinant of the rate of triglyceride synthesis within adipocytes. The major features of the pathway are described elsewhere [8] . In brief, human adipocytes synthesize and secrete the three proteins of the alternate complement pathway which interact to form a 77 amino terminal fragment of C3, the terminal arginine of which is removed by carboxypeptidases to produce ASP. ASP then interacts specifically with a receptor in the cell membrane [9] to activate a protein kinase C signal transduction pathway [10] which results in increased activity of Diabetologia (1997) 
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The pathogenetic role of impaired fatty acid trapping by adipocytes in generating the pleiotropic features of hyperapoB [11] , the last enzyme involved in the synthesis of a triglyceride molecule, and increased specific membrane transport of glucose [12, 13] . The latter effect is independent of, but additive to, that of insulin [12, 13] . As adipocytes differentiate and become larger, they become more competent to generate ASP and to respond to ASP [14, 15] . Both in vivo and in vitro evidence has established that chylomicrons stimulate the formation of ASP [16, 17] . The ASP pathway is, therefore, a unique regulatory metabolic system. The adipocyte produces the precursors and responds to the product. Moreover, the pathway in the adipocyte is activated by its physiologic target, the chylomicron, the net result being intricate and elegant metabolic regulation within the microenvironment.
Consequences of an impaired ASP pathway
Reduced functioning of the ASP pathway will produce a broad series of consequences. If NEFA concentration in the adipose tissue microenvironment rises due to decreased trapping efficiency by the adipocyte, excess NEFA will be delivered to the liver, LPL activity will be inhibited by product inhibition [18] , and triglyceride-rich chylomicron particles will be prematurely detached from the endothelial surface [19] . The reduced rate of triglyceride lipolysis by LPL and the generation and release into plasma of triglyceride-rich chylomicron remnants are both responsible for the delayed postprandial plasma triglyceride clearance that is characteristic of patients with hyperapoB [20] . In vitro and in vivo studies have established that increased delivery of NEFA or uptake of triglyceriderich remnants to the liver will cause the secretion rate of VLDL particles to increase [21, 22] . An increased secretion rate of VLDL will result in the increased generation of LDL particles. Many of these LDL particles will be smaller and denser than normal because of increased core lipid exchanges between VLDL and LDL [23] . These core lipid exchanges are further facilitated by higher ambient NEFA levels present in these patients. Accelerated core lipid exchanges have another consequence, namely the reduced HDL cholesterol that is also frequently present. Finally, abnormal NEFA metabolism has also been postulated to be the basis for the insulin resistance [24] which is also so common in this category of patient.
Defective ASP receptor function and omental obesity as causes of hyperapoB
The brief outline above sets out how a single, critically sited, metabolic defect -reduced trapping of fatty acids by adipocytes -could be responsible for all the lipoprotein manifestations of hyperapoB. Two common causes of the syndrome are ASP receptor defective hyperapoB and omental obesity. Studies with cultured human skin fibroblasts have shown that the effects of ASP on triglyceride synthesis are due to specific binding to a cell membrane receptor and that this receptor is deficient or defective in an important proportion of patients with hyperapoB [9] . Consequently, the maximal rate of adipocyte triglyceride synthesis -that is to say, fatty acid trapping -is reduced. Omental adipocytes are less effective than subcutaneous adipocytes at synthesizing triglycerides [25, 26] and therefore are also less effective at trapping fatty acids. Whatever the mechanism responsible, omental adipocytes -or more properly, any adipocyte with reduced triglyceride synthetic capacity -will produce the biologic consequences listed above when exposed to a high fatty acid intake.
